Literature DB >> 15122343

Raf promotes human herpesvirus-8 (HHV-8/KSHV) infection.

Shaw M Akula1, Patrick W Ford, Audy G Whitman, Khalief E Hamden, John G Shelton, James A McCubrey.   

Abstract

Human herpesvirus-8 (HHV-8/KSHV) is etiologically associated with Kaposi's sarcoma (KS) and other tumors. Constitutive activation of the mitogen-activated protein kinase (MAPK) signaling pathway has been associated with a variety of tumors, including AIDS-related KS. The oncoprotein Raf is situated at a pivotal position in regulating the MAPK pathway. Hence, we analysed the effect of oncoprotein Raf on HHV-8 infectious entry into target cells. Here we report Raf expression to significantly enhance HHV-8 infection of target cells. These findings implicate a role for Raf not only in the infectious entry of HHV-8 but also in modulating KS pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15122343     DOI: 10.1038/sj.onc.1207643

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

1.  Differential regulation of the attachment of Kaposi's sarcoma-associated herpesvirus (KSHV)-infected human B cells to extracellular matrix by KSHV-encoded gB and cellular alphaV integrins.

Authors:  Ossie F Dyson; Telisha L Oxendine; Khalief E Hamden; Patrick W Ford; Shaw M Akula
Journal:  Cell Microbiol       Date:  2008-03-25       Impact factor: 3.715

2.  Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway.

Authors:  Qi Zhang; Rui Gong; Jing Qu; Yijing Zhou; Weiyong Liu; Mingzhou Chen; Yingle Liu; Ying Zhu; Jianguo Wu
Journal:  J Virol       Date:  2011-11-23       Impact factor: 5.103

3.  Modulation of Kaposi's sarcoma-associated herpesvirus infection and replication by MEK/ERK, JNK, and p38 multiple mitogen-activated protein kinase pathways during primary infection.

Authors:  Hongyi Pan; Jianping Xie; Fengchun Ye; Shou-Jiang Gao
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity.

Authors:  Carisa A Zampieri; Jean-Francois Fortin; Garry P Nolan; Gary J Nabel
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

Review 5.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Ellis W T Wong; Fumin Chang; Brian Lehmann; David M Terrian; Michele Milella; Agostino Tafuri; Franca Stivala; Massimo Libra; Jorg Basecke; Camilla Evangelisti; Alberto M Martelli; Richard A Franklin
Journal:  Biochim Biophys Acta       Date:  2006-10-07

6.  Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway.

Authors:  Sarah M Battcock; Thaddeus W Collier; Dong Zu; Kensuke Hirasawa
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

7.  Activation of p90 ribosomal S6 kinase by ORF45 of Kaposi's sarcoma-associated herpesvirus and its role in viral lytic replication.

Authors:  Ersheng Kuang; Qiyi Tang; Gerd G Maul; Fanxiu Zhu
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

8.  Raf-induced vascular endothelial growth factor augments Kaposi's sarcoma-associated herpesvirus infection.

Authors:  Khalief E Hamden; Patrick W Ford; Audy G Whitman; Ossie F Dyson; Shi-Yuan Cheng; James A McCubrey; Shaw M Akula
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

9.  Systematic identification of cellular signals reactivating Kaposi sarcoma-associated herpesvirus.

Authors:  Fuqu Yu; Josephine N Harada; Helen J Brown; Hongyu Deng; Moon Jung Song; Ting-Ting Wu; Juran Kato-Stankiewicz; Christian G Nelson; Jeffrey Vieira; Fuyuhiko Tamanoi; Sumit K Chanda; Ren Sun
Journal:  PLoS Pathog       Date:  2007-03       Impact factor: 6.823

Review 10.  Human DNA Virus Exploitation of the MAPK-ERK Cascade.

Authors:  Jeanne K DuShane; Melissa S Maginnis
Journal:  Int J Mol Sci       Date:  2019-07-12       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.